Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2021-11-18 / Cancers (Basel) 2021 Nov;13(22)Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-11-11 / Prostate 2021 Nov;Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-02 / Cancers (Basel) 2021 Nov;13(21)Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-02 / Front Immunol 2021;12:770390The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-11-01 / Clin Neuropharmacol 2021 Nov-Dec 01;44(6):216-221Recent Advances in Experimental Dendritic Cell Vaccines for Cancer
/in Dendritic Cells, International Publications /von 2021-09-23 / Front Oncol 2021;11:730824Targeting CD166 lung cancer stem cells: Molecular study using murine dendritic cell vaccine
/in Dendritic Cells, International Publications, NSCLC, SCLC /von 2021-08-23 / Toxicol Appl Pharmacol 2021 Oct;429:115699Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-08-20 / Front Immunol 2021;12:669965IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de